Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA ... Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. Mehr anzeigen
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to...
Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously...
Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -8.23970037453 | 2.67 | 3.19 | 2.34 | 46654 | 2.68699543 | CS |
| 4 | 0.92 | 60.1307189542 | 1.53 | 6 | 1.44 | 2631642 | 2.85778103 | CS |
| 12 | 0.898 | 57.8608247423 | 1.552 | 6 | 1.44 | 3158478 | 2.88163655 | CS |
| 26 | -0.525 | -17.6470588235 | 2.975 | 6 | 1.44 | 1631637 | 2.82923462 | CS |
| 52 | -1.25 | -33.7837837838 | 3.7 | 6 | 1.44 | 1073846 | 2.86934702 | CS |
| 156 | -3.85 | -61.1111111111 | 6.3 | 16.2 | 0.423 | 2664099 | 1.37968823 | CS |
| 260 | -9.3 | -79.1489361702 | 11.75 | 19.2 | 0.423 | 1848645 | 2.56076786 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
